Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS

Executive Summary

After a three-day, three-drug advisory committee in November, the last sponsor standing - or at least the last to get a "complete response" letter from FDA - may be in the best position to move forward with its complicated skin and skin structure infections antibiotic

You may also be interested in...



FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.

FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.

Astellas, Theravance Get U.S. Approval With Vibativ, But HAP Indication Could Be Pushed To 2010

Japan's Astellas and Theravance's Vibativ (telavancin) gained U.S. FDA approval Sept. 11 for complicated skin infections, but an indication that will more sharply differentiate the drug may not see action until early 2010

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel